Core Viewpoint - HeartTech Medical (02291) reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its congenital heart disease occluder products and successful commercialization of new biodegradable devices [1] Financial Performance - Total revenue reached 330 million RMB, representing a year-on-year increase of 32.36% [1] - Net profit attributable to shareholders was 182 million RMB, up 29.81% year-on-year [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Performance - Sales revenue from congenital heart disease occluders increased from 129 million RMB for the six months ending June 30, 2024, to 161 million RMB for the same period in 2025, accounting for 51.6% and 48.7% of total revenue, respectively [1] - The growth in sales revenue is attributed to steady growth in traditional metal occluder products and successful commercialization of the fourth-generation MemoSorb® biodegradable septal occluder and atrial septal defect occluder [1] - The company is focusing on product iteration and differentiation through biodegradable technology [1]